Orphan designation: Odronextamab Treatment of diffuse large B-cell lymphoma, 18/07/2022 Positive
Orphan designation: Odronextamab Treatment of follicular lymphoma, 18/07/2022 Positive
Summary of opinion: Pegasys, 27/06/2024 Positive
Summary of opinion: Infanrix Hexa, 27/06/2024 Positive
Summary of opinion: Xalkori, 27/06/2024 Positive
Positive CHMP opinion on first-in-class medicine to treat pulmonary arterial hypertension
EMA recommends revoking conditional marketing authorisation for Ocaliva
First nasal adrenaline spray for emergency treatment against allergic reactions
Summary of opinion: Imfinzi, 27/06/2024 Positive
Summary of opinion: Lynparza, 27/06/2024 Positive